Mounjaro vs Ozempic in Canada: Key Differences
Quick answer: Mounjaro and Ozempic are different prescription medications. Mounjaro contains tirzepatide, while Ozempic contains semaglutide. As of August 2026, both Canadian product monographs include indications related to type 2 diabetes, but the approved populations and additional label statements are not identical. A licensed healthcare provider must decide whether either treatment is appropriate for an individual patient.
They are often discussed as though they are interchangeable. They are not. This guide explains the key differences in plain language, including approved uses in Canada, age groups, safety considerations, common side effects, and what a healthcare provider may review before making a treatment decision.
Important: This article is for educational purposes only. It does not replace medical advice. Product information and availability can change, so a licensed healthcare provider should review the current product monograph and an individual’s health history.
Mounjaro vs Ozempic at a Glance
| Feature | Mounjaro | Ozempic |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Prescription required in Canada | Yes | Yes |
| Canadian indication, summarized | Glycemic control in adults and certain patients aged 10 to under 18 with type 2 diabetes | Glycemic control in adults with type 2 diabetes, with additional cardiovascular and kidney risk-reduction indications for certain adults |
| Pediatric indication | The monograph includes certain patients aged 10 to under 18 | No approved pediatric indication is listed |
| Common reported side effects | Often gastrointestinal, including nausea, diarrhea, vomiting, constipation, or abdominal discomfort | Often gastrointestinal, including nausea, diarrhea, vomiting, constipation, or abdominal discomfort |
| Can they be used together? | Coadministration is not recommended. A licensed healthcare provider should manage any change between them. | |
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide. Its current Canadian product monograph includes use as an addition to diet and physical activity to improve glycemic control in adults with type 2 diabetes. The monograph also includes certain patients aged 10 to under 18 with type 2 diabetes, under specific clinical conditions.
The medication has its own contraindications, warnings, drug interaction considerations, and monitoring needs. It is not appropriate for everyone, and treatment requires a prescription.
What Is Ozempic?
Ozempic is the brand name for semaglutide. Its current Canadian product monograph includes use as an addition to diet and physical activity to improve glycemic control in adults with type 2 diabetes.
The monograph also includes additional indications for reducing certain cardiovascular risks in eligible adults with type 2 diabetes and established cardiovascular disease, and for reducing certain kidney and cardiovascular risks in eligible adults with type 2 diabetes and chronic kidney disease.
The monograph does not list an approved pediatric indication.
What Are the Main Differences?
1. They contain different active ingredients
Mounjaro contains tirzepatide. Ozempic contains semaglutide. These active ingredients are related but not the same, so the products are not interchangeable.
2. Their Canadian labels are not identical
Both product monographs include type 2 diabetes indications. However, the age groups and additional approved uses differ.
The Mounjaro monograph includes adults and certain patients aged 10 to under 18. The Ozempic monograph focuses on adults and includes added cardiovascular and kidney risk-reduction indications for certain eligible patients.
A label difference does not prove that one product is generally more suitable. It means a healthcare provider must match the treatment to the patient’s diagnosis, age, health history, and clinical needs.
3. Their precautions may affect different patients
Both product monographs include important warnings. A healthcare provider may need to review factors such as:
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- History of pancreatitis or gallbladder problems
- Kidney concerns or dehydration risk
- Severe gastrointestinal disease
- Diabetic eye disease
- Pregnancy, breastfeeding, or plans to become pregnant
- Other treatments that may increase the risk of low blood sugar
The details are not identical for every product or patient. The current monograph and a clinical assessment should guide the decision.
4. Coverage and availability can differ
Out-of-pocket cost and insurance coverage may depend on the prescribed treatment, approved indication, province, pharmacy pricing, private plan rules, and current supply. Coverage for one product does not guarantee coverage for the other.
How Does This Comparison Relate to Weight Management?
Many people research this topic while looking into medical weight management. That can make the comparison confusing because brand names, active ingredients, and approved indications are sometimes used as though they mean the same thing.
As of August 2026, the Canadian product monographs for these two brand-name products list indications centred on type 2 diabetes. Separate brand-name products and product monographs exist for chronic weight management. A licensed healthcare provider should confirm which indication and treatment category apply to an individual patient.
Changes in body weight may be measured in diabetes studies, but a study result does not turn one product into the right choice for every person. It also does not replace the approved Canadian label.
What Does Head-to-Head Research Tell Us?
A randomized clinical trial called SURPASS-2 compared tirzepatide with semaglutide in adults whose type 2 diabetes was not adequately controlled with metformin alone.
The study can help healthcare professionals understand differences under specific research conditions. It cannot answer which product is appropriate for every patient. The participants, treatment regimens, follow-up period, and study goals may not match an individual’s situation.
When reading comparisons online, check whether the article is discussing:
- A specific active ingredient or a brand-name product
- Type 2 diabetes or chronic weight management
- An approved Canadian indication or a research outcome
- A direct trial or an indirect comparison
- A population that resembles the person asking the question
What Do Mounjaro and Ozempic Have in Common?
Despite their differences, the two products have several similarities:
- Both require a prescription in Canada.
- Both require an individual medical assessment.
- Both have product-specific contraindications and warnings.
- Both may cause gastrointestinal side effects.
- Both may increase the risk of low blood sugar when used with certain other diabetes treatments.
- Both require follow-up when clinically indicated.
Side Effects and Safety Considerations
Commonly reported side effects for both products are mainly gastrointestinal. These may include nausea, diarrhea, vomiting, constipation, abdominal pain, or reduced appetite. The exact frequency and severity can vary.
More serious concerns can include pancreatitis, gallbladder problems, severe allergic reactions, kidney injury related to dehydration, and low blood sugar when used with certain other treatments. The product monographs also carry thyroid tumour warnings and contraindications for people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Seek urgent medical care for severe or persistent abdominal pain, trouble breathing, swelling of the face or throat, fainting, severe dehydration, or another sudden or concerning reaction.
Can You Take Mounjaro and Ozempic Together?
Coadministration is not recommended. Product monographs advise against combining these treatments with another GLP-1 receptor agonist.
Do not start, stop, overlap, or combine prescription treatments without direction from a licensed healthcare provider.
Can You Switch Between Them?
A switch may be considered in some situations, but it must be managed by a licensed healthcare provider. There is no universal conversion that applies to every patient.
A provider may review:
- The reason for the change
- Current glycemic control
- Side effects or tolerability concerns
- Other prescriptions and health conditions
- Cardiovascular or kidney history
- Insurance coverage and availability
Do not use leftover medication or copy another person’s treatment plan.
Is One More Suitable Than the Other?
There is no single answer for everyone. The more appropriate option depends on the approved indication and the patient’s full health profile.
For example, a provider may consider age, type 2 diabetes history, cardiovascular disease, chronic kidney disease, eye health, previous reactions, other prescriptions, pregnancy plans, and the ability to attend follow-up care.
The most useful comparison is not which product receives the strongest claim online. It is which treatment, if any, matches the patient’s diagnosis and can be used with an acceptable risk profile.
Questions to Discuss With a Healthcare Provider
- Which approved indication applies to my health situation?
- Do my current prescriptions create interaction or low blood sugar concerns?
- Does my cardiovascular, kidney, eye, thyroid, pancreas, or gallbladder history affect eligibility?
- What side effects should I watch for?
- What follow-up or testing may be needed?
- What does my insurance plan cover for the approved indication?
- What should I do if the prescribed product is unavailable?
Frequently Asked Questions
What is the main difference between Mounjaro and Ozempic?
Mounjaro contains tirzepatide, while Ozempic contains semaglutide. Their Canadian product monographs also differ in approved age groups and additional indications.
Are Mounjaro and Ozempic the same medication?
No. They contain different active ingredients and are not interchangeable.
Are these products approved for chronic weight management in Canada?
The current Canadian product monographs for these two brand-name products list indications centred on type 2 diabetes. Separate brand-name products and product monographs exist for chronic weight management.
Is one more suitable than the other?
Not for everyone. Suitability depends on the approved indication, age, health history, other prescriptions, risks, coverage, and a licensed healthcare provider’s assessment.
Can Mounjaro and Ozempic be used together?
Coadministration is not recommended. A licensed healthcare provider should manage any treatment change.
Can someone switch from one to the other?
A healthcare provider may consider a switch after reviewing the reason for the change, current treatment, health history, side effects, and other prescriptions. Patients should not switch or overlap them on their own.
What side effects do they share?
Both may cause gastrointestinal effects such as nausea, diarrhea, vomiting, constipation, or abdominal discomfort. Serious reactions are less common but require prompt medical attention.
Do you need a prescription in Canada?
Yes. Both are prescription medications. A licensed healthcare provider must determine whether treatment is clinically appropriate.
Does insurance cover them?
Coverage varies by plan, province, indication, and eligibility rules. Patients should confirm coverage directly with their insurer.
Key Takeaways
- Mounjaro and Ozempic are different prescription medications.
- Both Canadian monographs include type 2 diabetes indications, but their labels are not identical.
- The Mounjaro monograph includes certain patients aged 10 to under 18; the Ozempic monograph does not list a pediatric indication.
- The Ozempic monograph includes additional cardiovascular and kidney risk-reduction indications for certain adults.
- Coadministration is not recommended, and switching should be managed by a licensed healthcare provider.
- Neither product is appropriate for everyone.
Sources Reviewed
You Might Also Like
Learn more about our treatments
